These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26177543)

  • 21. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
    Vuilleumier N; Charbonney E; Fontao L; Alvarez M; Turck N; Sanchez JC; Burkhard PR; Mensi N; Righini M; Reber G; James R; Mach F; Chevrolet JC; Dayer JM; Frostegard J; Roux-Lombard P
    Clin Sci (Lond); 2008 Jul; 115(1):25-33. PubMed ID: 18088236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus.
    Abe H; Tsuboi N; Suzuki S; Sakuraba H; Takanashi H; Tahara K; Tonozuka N; Hayashi T; Umeda M
    J Rheumatol; 2001 May; 28(5):990-5. PubMed ID: 11361227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes.
    Carbone F; Satta N; Montecucco F; Virzi J; Burger F; Roth A; Roversi G; Tamborino C; Casetta I; Seraceni S; Trentini A; Padroni M; Dallegri F; Lalive PH; Mach F; Fainardi E; Vuilleumier N
    Eur J Clin Invest; 2016 Sep; 46(9):805-17. PubMed ID: 27490973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contributions of the N- and C-terminal helical segments to the lipid-free structure and lipid interaction of apolipoprotein A-I.
    Tanaka M; Dhanasekaran P; Nguyen D; Ohta S; Lund-Katz S; Phillips MC; Saito H
    Biochemistry; 2006 Aug; 45(34):10351-8. PubMed ID: 16922511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
    Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
    J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A three-dimensional molecular model of lipid-free apolipoprotein A-I determined by cross-linking/mass spectrometry and sequence threading.
    Silva RA; Hilliard GM; Fang J; Macha S; Davidson WS
    Biochemistry; 2005 Mar; 44(8):2759-69. PubMed ID: 15723520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy.
    Vuilleumier N; Montecucco F; Spinella G; Pagano S; Bertolotto M; Pane B; Pende A; Galan K; Roux-Lombard P; Combescure C; Dallegri F; Mach F; Palombo D
    Thromb Haemost; 2013 Apr; 109(4):706-15. PubMed ID: 23364307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes.
    Mannic T; Satta N; Pagano S; Python M; Virzi J; Montecucco F; Frias MA; James RW; Maturana AD; Rossier MF; Vuilleumier N
    Endocrinology; 2015 Dec; 156(12):4707-19. PubMed ID: 26393305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of amino acid distribution of amphipathic helical peptide derived from human apolipoprotein A-I on membrane curvature sensing.
    Tanaka M; Takamura Y; Kawakami T; Aimoto S; Saito H; Mukai T
    FEBS Lett; 2013 Mar; 587(5):510-5. PubMed ID: 23347831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion.
    Vecchié A; Bonaventura A; Carbone F; Maggi D; Ferraiolo A; Carloni B; Andraghetti G; Affinito Bonabello L; Liberale L; Fetaud V; Pagano S; Dallegri F; Cordera R; Montecucco F; Vuilleumier N
    Biomed Res Int; 2020; 2020():9309121. PubMed ID: 32219148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chameleon 'aggregation-prone' segments of apoA-I: A model of amyloid fibrils formed in apoA-I amyloidosis.
    Louros NN; Tsiolaki PL; Griffin MD; Howlett GJ; Hamodrakas SJ; Iconomidou VA
    Int J Biol Macromol; 2015 Aug; 79():711-8. PubMed ID: 26049118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis.
    Wick PA; Mombelli A; Pagano S; Moren X; Giannopoulou C; Mach F; Roux-Lombard P; Vuilleumier N
    J Periodontal Res; 2013 Jun; 48(3):350-6. PubMed ID: 23050768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I.
    Wong YQ; Binger KJ; Howlett GJ; Griffin MD
    FEBS Lett; 2012 Jun; 586(13):1754-8. PubMed ID: 22609356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
    Carballo-Jane E; Chen Z; O'Neill E; Wang J; Burton C; Chang CH; Chen X; Eveland S; Frantz-Wattley B; Gagen K; Hubbard B; Ichetovkin M; Luell S; Meurer R; Song X; Strack A; Langella A; Cianetti S; Rech F; Capitò E; Bufali S; Veneziano M; Verdirame M; Bonelli F; Monteagudo E; Pessi A; Ingenito R; Bianchi E
    Bioorg Med Chem; 2010 Dec; 18(24):8669-78. PubMed ID: 21115285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein A-I peptide models as probes to formulate potential inhibitors of the low-density lipoprotein oxidation.
    Darvari MI; Petraki MP; Tellis C; Harilogis K; Tselepis AD; Sakarellos-Daitsiotis M
    J Pept Sci; 2011 Nov; 17(11):720-5. PubMed ID: 21948303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural studies of N- and C-terminally truncated human apolipoprotein A-I.
    Fang Y; Gursky O; Atkinson D
    Biochemistry; 2003 Jun; 42(22):6881-90. PubMed ID: 12779343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deletion of central alpha-helices in human apolipoprotein A-I: effect on phospholipid association.
    Frank PG; Bergeron J; Emmanuel F; Lavigne JP; Sparks DL; Denèfle P; Rassart E; Marcel YL
    Biochemistry; 1997 Feb; 36(7):1798-806. PubMed ID: 9048564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein A-I (ApoA-I) mimetic peptide P2a by restoring cholesterol esterification unmasks ApoA-I anti-inflammatory endogenous activity in vivo.
    Bucci M; Cigliano L; Vellecco V; D'Andrea LD; Ziaco B; Rossi A; Sautebin L; Carlucci A; Abrescia P; Pedone C; Ianaro A; Cirino G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):716-22. PubMed ID: 22171091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microenvironmentally controlled secondary structure motifs of apolipoprotein A-I derived peptides.
    Mendoza-Espinosa P; Montalvan-Sorrosa D; García-González V; Moreno A; Castillo R; Mas-Oliva J
    Mol Cell Biochem; 2014 Aug; 393(1-2):99-109. PubMed ID: 24748322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of apolipoprotein A-I lipidation on the formation and function of pre-beta and alpha-migrating LpA-I particles.
    Sparks DL; Frank PG; Braschi S; Neville TA; Marcel YL
    Biochemistry; 1999 Feb; 38(6):1727-35. PubMed ID: 10026251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.